Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.52 |
| ▸ | GSK3B | P49841 | 9/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.36 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13289440 | 0.93 | CDK2 (0.51) | CDK2GSK3BCCNA2CCNA1NPY5R | |
| SCHEMBL13289430 | 0.93 | GSK3B (0.49) | CDK2GSK3BCCNA2CCNA1NPY5R | |
| SCHEMBL12954278 | 0.91 | CDK2 (0.52) | CDK2GSK3BCCNA2CCNA1ALDH1A1 | |
| SCHEMBL13289239 | 0.90 | GSK3B (0.51) | CDK2GSK3BCCNA2CCNA1MEN1 | |
| SCHEMBL13120640 | 0.90 | CDK2 (0.67) | CDK2GSK3BCCNA2CCNA1 | |
| SCHEMBL13289375 | 0.90 | CDK2 (0.54) | CDK2GSK3BCCNA2CCNA1MEN1 | |
| SCHEMBL13288963 | 0.89 | CDK2 (0.46) | CDK2GSK3BCCNA2CCNA1NPY5R | |
| SCHEMBL13289429 | 0.88 | CDK2 (0.49) | CDK2GSK3BCCNA2CCNA1RAB9A | |
| SCHEMBL13289431 | 0.88 | CDK2 (0.49) | CDK2GSK3BCCNA2CCNA1MEN1 | |
| SCHEMBL13288973 | 0.87 | CDK2 (0.48) | CDK2GSK3BCCNA2CCNA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2007044449-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CDK2 1/4885GSK3B 695/4885CCNA2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.